MOLECURE S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.72 PLN | -4.29% |
|
+1.66% | -24.51% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
Calendar
26/09/2024
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.38
PLN
Average target price
34
PLN
Spread / Average Target
+121.07%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.51% | 65.58M | |
| +7.43% | 111B | |
| +11.27% | 106B | |
| -12.70% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.70% | 16.81B | |
| +37.48% | 12.54B | |
| -23.94% | 8.09B |
- Stock Market
- Equities
- MOC Stock
- News Molecure S.A.
- Poland's Molecure Doses First Patient in Cancer Treatment Trial
